Valuation: Freenome, Inc.

Market Cap 1.72B 1.51B 1.42B 1.3B 2.43B 165B 2.45B 17.04B 6.6B 84.13B 6.45B 6.31B 270B P/E 2026 *
-8.12x
P/E 2027 * -7.16x
Enterprise Value 1.72B 1.51B 1.42B 1.3B 2.43B 165B 2.45B 17.04B 6.6B 84.13B 6.45B 6.31B 270B EV / Sales 2026 *
16.8x
EV / Sales 2027 * 15.1x
Free-Float
74.05%
Yield 2026 *
-
Yield 2027 * -
1 day-4.59%
1 week-8.24%
Current month+6.15%
1 month+11.43%
3 months+43.64%
6 months+45.24%
Current year+20.49%
1 week 15.28
Extreme 15.28
17.5
1 month 13.81
Extreme 13.81
17.5
Current year 9.95
Extreme 9.95
17.5
1 year 9.95
Extreme 9.95
17.5
3 years 9.95
Extreme 9.95
17.5
5 years 9.95
Extreme 9.95
17.5
10 years 9.95
Extreme 9.95
17.5
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Chief Executive Officer

-71,920 0.0669%
7/20/26 Other

Chief Executive Officer

835,791 0.3889%
7/20/26 Conversion -30,000 1.3913%
Change 5-day change 1-year change 3-year change Capi.($)
-4.59%-8.24%+48.11% - 1.72B
+1.85%+7.32%+421.33%+147.75% 4.98B
-0.47%+2.87%+122.62%+429.32% 4.7B
-6.41%+14.16%+35.86%+101.20% 3.65B
+3.76%+18.30%+326.52%+765.22% 3.29B
+2.50%+13.65%-7.45%-14.14% 2.58B
-0.58%+0.59%+36.00%+63.46% 1.14B
-0.65%+9.04%+169.50%-16.85% 1.13B
+5.08%+8.18%-21.14%+142.84% 629M
-1.62%+1.94%-30.43%-17.53% 529M
Average -0.11%+6.85%+110.09%+177.92% 2.44B
Weighted average by Cap. -0.19%+8.45%+170.35%+253.59%

Financials

2026 *2027 *
Net sales 102M 89.87M 84.88M 77.35M 145M 9.82B 146M 1.02B 393M 5.01B 385M 376M 16.12B 114M 99.89M 94.34M 85.98M 161M 10.91B 162M 1.13B 437M 5.57B 427M 418M 17.91B
Net income -175M -154M -145M -132M -248M -16.78B -249M -1.74B -673M -8.57B -657M -643M -27.56B -246M -216M -204M -186M -347M -23.55B -350M -2.44B -944M -12.03B -923M -903M -38.67B
Net Debt - -
Logo Freenome, Inc.
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
Employees
378
Date Price Change Volume
26-09-25 US$15.99 -0.12% 418,854
26-09-24 US$16.01 +1.97% 507,868
26-09-23 US$15.70 -4.59% 578,478
26-09-22 US$16.46 -0.87% 568,001
26-09-21 US$16.60 -2.98% 588,227
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.99USD
Average target price
18.00USD
Spread / Average Target
+12.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FRNM Stock